BioXcel’s Phase 3 Trial Success for BXCL501

Bioxcel Therapeutics ( (BTAI) ) has shared an update.

On August 27, 2025, BioXcel Therapeutics announced that its SERENITY At-Home Pivotal Phase 3 trial for BXCL501 met its primary endpoint, demonstrating safety and tolerability for treating agitation in bipolar disorder and schizophrenia patients at home. This successful trial supports the planned sNDA submission for IGALMI® label expansion in early 2026, potentially addressing a significant unmet need in the at-home treatment market, which is estimated to involve 57 to 77 million annual agitation episodes in the U.S.

The most recent analyst rating on (BTAI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.

Spark’s Take on BTAI Stock

According to Spark, TipRanks’ AI Analyst, BTAI is a Underperform.

Bioxcel Therapeutics’ stock is rated at the lowest end of the scale due to substantial financial instability, including ongoing losses, high debt, and negative cash flows. Short-term technical indicators and valuation metrics further highlight the current challenges. The company needs to address these financial and operational issues to improve its stock performance.

To see Spark’s full report on BTAI stock, click here.

More about Bioxcel Therapeutics

BioXcel Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development of innovative medicines using artificial intelligence. The company primarily works on treatments for neuropsychiatric disorders, with its key product being BXCL501, a sublingual film formulation of dexmedetomidine, used for treating agitation associated with bipolar disorders and schizophrenia.

Average Trading Volume: 8,448,446

Technical Sentiment Signal: Sell

Current Market Cap: $76.28M

For detailed information about BTAI stock, go to TipRanks’ Stock Analysis page.